Revenue
No reported data
Liminatus Pharma, Inc. (LIMN)
Price—Loading quote
Net income
2024
2025
Free cash flow
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | — | $2.7M |
| Operating expenses | $3.0M | $3.3M |
| Operating income | −$3.0M | −$3.3M |
| Net income | −$10.2M | −$3.5M |
| Basic EPSper diluted share | -$0.43 | -$0.20 |
| Diluted EPSper diluted share | -$0.43 | -$0.20 |